Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Incidence of GM-CSF antibodies in cancer patients receiving GM-CSF for immunostimulation
Autore:
Ullenhag, G; Bird, C; Ragnhammar, P; Frodin, JE; Strigard, K; Osterborg, A; Thorpe, R; Mellstedt, H; Wadhwa, M;
Indirizzi:
Karolinska Hosp, Canc Ctr Karolinska, S-10401 Stockholm, Sweden KarolinskaHosp Stockholm Sweden S-10401 nska, S-10401 Stockholm, Sweden Karolinska Hosp, Dept Hematol, S-10401 Stockholm, Sweden Karolinska Hosp Stockholm Sweden S-10401 atol, S-10401 Stockholm, Sweden Karolinska Hosp, Radiumhemmet, Dept Oncol, S-10401 Stockholm, Sweden Karolinska Hosp Stockholm Sweden S-10401 ncol, S-10401 Stockholm, Sweden Huddinge Univ Hosp, Dept Surg, Stockholm, Sweden Huddinge Univ Hosp Stockholm Sweden Hosp, Dept Surg, Stockholm, Sweden Univ Uppsala Hosp, Dept Oncol, S-75185 Uppsala, Sweden Univ Uppsala Hosp Uppsala Sweden S-75185 Oncol, S-75185 Uppsala, Sweden Natl Inst Biol Stand & Controls, Div Immunobiol, Potters Bar EN6 3QG, Herts, England Natl Inst Biol Stand & Controls Potters Bar Herts England EN6 3QG England
Titolo Testata:
CLINICAL IMMUNOLOGY
fascicolo: 1, volume: 99, anno: 2001,
pagine: 65 - 74
SICI:
1521-6616(200104)99:1<65:IOGAIC>2.0.ZU;2-1
Fonte:
ISI
Lingua:
ENG
Soggetto:
COLONY-STIMULATING FACTOR; MONOCLONAL-ANTIBODIES; COMBINATION THERAPY; IMMUNE-RESPONSE; DENDRITIC CELLS; FACTOR AUGMENTS; CYTO-TOXICITY; TUMOR-CELLS; VACCINATION; ANTIGEN;
Keywords:
cancer vaccine; monoclonal antibodies; colorectal carcinoma; myeloma; antibodies; cytokine; therapy; binding; neutralizing;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
32
Recensione:
Indirizzi per estratti:
Indirizzo: Ullenhag, G Karolinska Hosp, Canc Ctr Karolinska, S-10401 Stockholm, Sweden Karolinska Hosp Stockholm Sweden S-10401 1 Stockholm, Sweden
Citazione:
G. Ullenhag et al., "Incidence of GM-CSF antibodies in cancer patients receiving GM-CSF for immunostimulation", CLIN IMMUNO, 99(1), 2001, pp. 65-74

Abstract

We have assessed the immunogenicity profile of GM-CSF in patients with either colorectal carcinoma (CRC) at different stages of disease or with multiple myeloma who were given recombinant human GMCSF (Escherichia coli-derived) combination therapy. Metastatic CRC patients received a colon carcinoma-reactive antibody and high doses of GM-CSF (425-500 mug/day for 10 days), while other CRC patients and those with myeloma received low doses of GM-CSF(75-80 mug/day for 4 days) as an adjuvant along with appropriate tumor antigens. We found that 55% of the patients (11/20) given high doses of GM-CSFdeveloped GM-CSF-reactive antibodies in comparison with an incidence of only 16% (4/25) in patients given low doses of GM-CSF. None of the patients developed neutralizing antibodies and so the biological effects of GM-CSF were not compromised. A majority of patients (80%) (36/45) also developed antibodies to E. coli proteins that were present as trace contaminants in the GMCSF product. Treatment with recombinant GM-CSF products, therefore, may induce antibodies against this cytokine depending on the regimen and the amounts used. In this study, multiple immunizations with low doses of GI M-CSFwas associated with a low incidence of GM-CSF antibodies, which did not neutralize the effect of the cytokine. This therapeutic strategy was effective in inducing adjuvant-type effects and needs to be explored in further clinical trials with this cytokine, (C) 2001 Academic Press.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/01/20 alle ore 15:57:06